This Article  • Full text  • PDF  • Author in the Room Audio  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Immunization  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael E. Pichichero, MD; Margaret B. Rennels, MD; Kathryn M. Edwards, MD; Mark M. Blatter, MD; Gary S. Marshall, MD; Monica Bologa, MD, MS; Elaine Wang, MD; Elaine Mills, MD

JAMA. 2005;293:3003-3011. Published online June 2, 2005 (doi:10.1001/jama.293.24.3003).

Context  Increasing reports of pertussis among US adolescents, adults, and their infant contacts have stimulated vaccine development for older age groups.

Objective  To assess the immunogenicity and reactogenicity of a tetanus-diphtheria 5-component (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3) acellular pertussis vaccine (Tdap) in adolescents and adults.

Design, Setting, and Participants  A prospective, randomized, modified double-blind, comparative trial was conducted in healthy adolescents and adults aged 11 through 64 years from August 2001 to August 2002 at 39 US clinical centers.

Interventions  A single 0.5-mL intramuscular dose of either Tdap or tetanus-diphtheria vaccine (Td).

Main Outcome Measures  Antibody titers to diphtheria and tetanus toxoids for Tdap and Td were measured in sera collected from subsets of adolescents and adults, before and 28 days after vaccination. For pertussis antigens, titers in sera from Tdap vaccinees were assessed vs those from infants who received analogous pediatric diphtheria-tetanus-acellular pertussis vaccine (DTaP) in a previous efficacy trial. Safety was assessed via solicited local and systemic reactions for 14 days and adverse events for 6 months following vaccination.

Results  A total of 4480 participants were enrolled. For both Tdap and Td, more than 94% and nearly 100% of vaccinees had protective antibody concentrations of at least 0.1 IU/mL for diphtheria and tetanus, respectively. Geometric mean antibody titers to pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3 exceeded (by 2.1 to 5.4 times) levels in infants following immunization at 2, 4, and 6 months with DTaP. The incidence of solicited local and systemic reactions and adverse events was generally similar between the Tdap and Td groups.

Conclusions  This Tdap vaccine elicited robust immune responses in adolescents and adults to pertussis, tetanus, and diphtheria antigens, while exhibiting an overall safety profile similar to that of a licensed Td vaccine. These data support the potential routine use of this Tdap vaccine in adolescents and adults.

Author Affiliations: University of Rochester Medical Center, Rochester, NY (Dr Pichichero); University of Maryland, Baltimore (Dr Rennels); Vanderbilt University, Nashville, Tenn (Dr Edwards); Primary Physicians Research, Pittsburgh, Pa (Dr Blatter); University of Louisville, Louisville, Ky (Dr Marshall); Sanofi Pasteur Limited, Toronto, Ontario (Drs Bologa, Wang, and Mills).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

New Combination Vaccine
Tracy Hampton
JAMA. 2005;293(24):2992.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months: A Randomized Trial
Marano et al.
JAMA 2008;300:1532-1543.
ABSTRACT | FULL TEXT  

Pertussis Vaccination for Health Care Workers
Sandora et al.
Clin. Microbiol. Rev. 2008;21:426-434.
ABSTRACT | FULL TEXT  

Predicting Pertussis in a Pediatric Emergency Department Population
Mackey et al.
CLIN PEDIATR 2007;46:437-440.
ABSTRACT  

Pertussis Infection in the United States: Role for Vaccination of Adolescents and Adults
Brooks and Clover
J Am Board Fam Med 2006;19:603-611.
ABSTRACT | FULL TEXT  

Rationale for Use of Tdap Booster Vaccines for Adolescent Immunization: Overview of Efficacy, Safety, and Clinical Use
Hitchcock
CLIN PEDIATR 2006;45:785-794.
ABSTRACT  

Acellular Pertussis Vaccine Boosters Combined With Diphtheria and Tetanus Toxoid Boosters for Adolescents: Safety and Immunogenicity Assessment When Preceded by Different 5-Dose DTaP/DTwP Schedules
Pichichero et al.
CLIN PEDIATR 2006;45:613-620.
ABSTRACT  

The 5 component acellular pertussis vaccine combined with tetanus and diphtheria toxoids was efficacious in adolescents and adults
Datta
Evid. Based Med. 2006;11:51-51.
FULL TEXT  

Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents
Pichichero et al.
Pediatrics 2006;117:1084-1093.
ABSTRACT | FULL TEXT  

Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine
Committee on Infectious Diseases
Pediatrics 2006;117:965-978.
ABSTRACT | FULL TEXT  

Journal Watch
Arch. Dis. Child. 2005;90:1316-1317.
FULL TEXT  

The Growing Paradigm of Preventing Disease: Vaccines To Prevent Herpes Zoster and Pertussis in Adults
Poland
ANN INTERN MED 2005;143:539-541.
FULL TEXT  

Now Approved: Tetanus-Diphtheria-Pertussis Booster for Adolescents and Adults
JWatch Pediatrics 2005;2005:4-4.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2005;331:71-72.
FULL TEXT  

Pertussis Vaccine Safe and Immunogenic in Adolescents and Adults
JWatch Infect. Diseases 2005;2005:2-2.
FULL TEXT